Abstract
AIM: To investigate the expression of ezrin, focal adhesion kinase (FAK) arid E-cadherin (E-cad) as well as their correlations with the invasion and metastasis of colorectal carcinoma. METHODS: Immunohistochemistry was used to detect the expression of ezrin, FAK and E-cad in 50 cases of colorectal carcinoma (including 13 well-differentiated adencarcinomas, 37 moderately- or poorly-differentiated adenocarcinomas; 30 cases without lymph node metastasis and 20 with lymph node metastasis). The correlations among Ezrin, FAK and E-cadherin expression as well as the clinical and pathological characteristics were analyzed by statistical method. RESULTS: The expression of ezrin was significantly higher in colorectal carcinomas with moderate or poor differention, lymph node metastasis and pukes C+D stages than that in the ones with high differention, non-metastasis, and Dukes A+B stages (83.78% vs 46.15%, P＜0.01; 95.00% vs 60.00%, P＜0.01; 95.00% vs 60.00%, P＜0.01), but E-cad expression was in the contrary situation (24.32% vs 69.23%, P＜0.01; 10.00% vs 53.33%, P＜0.01; 10.00% vs 53.33%, P＜0.01). The expression of ezrin and E-cad had no marked correlations with the age and sex of patients (P＞0.05). FAK expression was markedly higher in colorectal carcinomas with Dukes C+D stages and lymph node metastasis than that in the ones with Dukes A+B stages and without metastasis (100.00% us 63.33%, P＜0.01; 100.00% vs 63.33%, P＜0.01), but it had no significant correlation with the differetion degree of tumors, the sex and ages of patients (P＞0.05). Spearman analysis showed that there existed positive correlation between Ezrin and FAK expression (r = 0.346, P＜0.05), and negative correlation between E-cadherin and Ezrin (r = -0.410, P＜0.01) as well as E-cadherin and FAK expression (r -0.406, P＜0.01). CONCLUSION: The abnormal expression of ezrin, FAK and E-cad are closely correlated with the infiltration and metastasis of colorectal carcinoma, and the combined detection can be used to judge the prognosis of patients with colorectal carcinoma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
